Transcarent

Workforce health benefits platform — completed $621M Accolade merger; serves 20M+ members across 1,700+ employer/health-plan clients.

Services Health Tech / Workforce Benefits
New (0 reviews)
San Francisco, CA, USA HQ
3,000 employees
2020 founded

What is Transcarent?

Transcarent is a workforce-health and care-experience platform founded in 2020 by Glen Tullman, the former CEO of Livongo (which sold to Teladoc for $18.5B in 2020). Headquartered in San Francisco, the company helps self-insured employers and health plans deliver a unified, AI-powered member experience across pharmacy, surgery, cancer care, weight health, mental health, and primary/specialty care. In April 2025 Transcarent completed a $621M cash merger with Accolade — combining one of the largest direct-to-employer benefits-navigation platforms with Transcarent's health-experience stack. The combined organization now serves more than 20M members and 1,700+ employer/health-plan clients. Pre-merger, Transcarent raised $450M+ across 4 rounds — $200M Series C in 2022 and a $126M Series D in May 2024 led by General Catalyst and 7wireVentures, valuing the company at $2.2B before the Accolade transaction. Snezana Mahon, Pharm.D., was promoted to President in late 2024.

Mission & values

Make it easy for everyone to get great healthcare — give members and the employers who cover them a single trusted front door for every health and care decision.

Qualifications

Transcarent hires across engineering (data, ML/AI, platform, mobile, infrastructure), product, design, clinical (RNs, NPs, MDs, pharmacists, behavioral-health clinicians), care navigation, member services, sales, customer success, marketing, finance, legal, and people. Most non-clinical roles are US-remote-friendly with the SF HQ + Plymouth Meeting PA (legacy Accolade hub) + a major Indian operations footprint absorbed via the merger. Clinical roles (telehealth providers, care advocates) require state-by-state licensure aligned with member populations and are remote-eligible within those states. Apply via transcarent.com/careers.

Leadership

G

Glen Tullman

Chief Executive Officer

Founder & CEO of Transcarent; previously founder/CEO of Livongo (NASDAQ: LVGO, sold to Teladoc for $18.5B in 2020). Also founder of 7wireVentures and 62 Ventures.

S

Snezana Mahon, PharmD

President

Promoted to President in late 2024; previously COO at Transcarent. Pharm.D. by training with 20+ years in pharmacy benefits and member-experience operations.

R

Rajeev Singh

Vice Chair (former Accolade CEO)

Co-founder and former CEO of Accolade; transitioned to Vice Chair after the April 2025 merger.

Hiring process

  1. 1

    Application

    Apply via transcarent.com/careers and select a role that matches your skill set.

  2. 2

    Recruiter screen

    Initial conversation to confirm fit, location, and licensure (for clinical roles).

    About 3 days

  3. 3

    Hiring manager interview

    Role-specific deep-dive with the team's manager.

    About 5 days

  4. 4

    Functional / clinical loop

    Multi-round interviews — system design + coding for eng; case studies for product/GTM; clinical skills review for licensed providers.

    About 10 days

  5. 5

    Offer + credentialing

    Final values fit, comp discussion, and (for clinical roles) state-by-state credentialing kickoff.

    About 7 days

Funding

StageSeries C+
Total raised$450,000,000
Investors
General Catalyst 7wireVentures Glen Tullman / 62 Ventures JPMorgan (debt for Accolade merger) Kinnevik Geodesic Capital

Awards & recognition

  • $621M merger with Accolade completed · 2025

    Transcarent

  • $2.2B valuation at $126M Series D · 2024

    General Catalyst / 7wireVentures

  • Glen Tullman recognized as a healthcare visionary (Livongo founder) · 2020

    Industry

  • 20M+ members and 1,700+ clients on combined platform · 2025

    Transcarent

Company information

Frequently asked questions

Who founded Transcarent?
Glen Tullman — the former CEO of Livongo (sold to Teladoc for $18.5B in 2020). Transcarent launched in 2020.
What is the Accolade merger?
In April 2025 Transcarent completed a $621M cash merger with Accolade ($7.03/share for Accolade shareholders). The combined company serves 20M+ members and 1,700+ employer/health-plan clients.
How big is the combined team?
Pre-merger Transcarent had ~550 employees; combined with Accolade post-merger the workforce is approximately 3,000+ globally.
Who are the executives?
Glen Tullman remains CEO. Snezana Mahon, Pharm.D., is President. Former Accolade CEO Rajeev Singh transitioned to Vice Chair.
How much has Transcarent raised?
About $450M+ in equity over 4 rounds, plus a $621M cash merger with Accolade financed by General Catalyst, 62 Ventures, and JPMorgan-led debt. Pre-merger valuation $2.2B.
Are roles remote?
Most non-clinical roles are US-remote-friendly with SF HQ + Plymouth Meeting, PA + an Indian operations footprint absorbed via Accolade. Clinical roles are remote within licensed states.
How can I apply?
Browse open roles at transcarent.com/careers.

Stay in the loop.

One email per week, 5 hand-picked roles.